Adagene Inc. (ADAG)
- Previous Close
2.6500 - Open
2.6400 - Bid --
- Ask --
- Day's Range
2.6500 - 2.6500 - 52 Week Range
1.1000 - 4.3800 - Volume
435 - Avg. Volume
35,009 - Market Cap (intraday)
117.016M - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4400 - Earnings Date Mar 28, 2024 - Apr 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.
www.adagene.comRecent News: ADAG
Performance Overview: ADAG
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADAG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADAG
Valuation Measures
Market Cap
117.02M
Enterprise Value
29.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.41
Price/Book (mrq)
1.66
Enterprise Value/Revenue
1.62
Enterprise Value/EBITDA
-1.97
Financial Highlights
Profitability and Income Statement
Profit Margin
-104.61%
Return on Assets (ttm)
-11.06%
Return on Equity (ttm)
-24.66%
Revenue (ttm)
18.11M
Net Income Avi to Common (ttm)
-18.95M
Diluted EPS (ttm)
-0.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
109.93M
Total Debt/Equity (mrq)
31.61%
Levered Free Cash Flow (ttm)
-23.52M